The c.673T>C variant in GP1BA is a missense variant predicted to cause substitution of Cysteine by Arginine at amino acid 225 (p.Cys225Arg). At least one patient (internal case from Versiti) with this variant had less than 10% expression of GPIba measured by flow cytometry, which is highly specific for Bernard-Soulier syndrome, the patient also had excessive mucocutaneous bleeding consistent with Bernard-Soulier syndrome (PP4). This individual was compound heterozygous for this variant and the NM_000173.7(GP1BA):c.1601_1602del (p.Tyr534CysfsTer?) variant which was classified as Pathogenic by the PD VCEP. The phase of the variants in this patient is unknown (0.5 points, PM3_Supporting). This variant resides at a disulfide bond residue, Cys225 GP1BA that is defined as a critical functional domain by the ClinGen PD VCEP (PM1). The largest population MAF allele frequency in gnomAD v4.1.0 is 0.000001695 (based on 2/1179886 alleles) in the European (non-Finnish) population, which is lower than the ClinGen PD VCEP threshold (<0.0001114; PM2_Supporting). The computational predictor REVEL gives a score of 0.653, which is above the ClinGen PD VCEP threshold of >0.644 and predicts a damaging effect on function (PP3). Another missense variant (c.673T>A, p.Cys225Ser) in the same codon has been classified as Pathogenic for Bernard-Soulier syndrome by the ClinGen PD VCEP (PM5). In summary, this variant meets the criteria to be classified as Likely Pathogenic for autosomal recessive Bernard-Soulier syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PP4, PM1, PM5, PM2_Supporting, PM3_supporting and PP3 (VCEP specifications version 1).